The case for & against
Bull & Bear analysis
Bullish
Adverum Biotechnologies Inc. (NASDAQ: ADVM) is a clinical-stage biotechnology company focused on developing gene therapies specifically targeting ocular diseases, with a strong emphasis on wet age-related macular degeneration (wet AMD). The company is positioned to potentially revolutionize treatment paradigms by providing one-time therapies that address significant unmet medical needs related to vision loss.
Bull says
- ↑ADVM-022 trials show 99% reduction in anti-VEGF injections
- ↑OPTIC trial fully enrolled 300 patients ahead of schedule
- ↑67% of patients injection-free at 48-week evaluation
- ↑Two global Phase III trials target ~900 treatment-naive patients
- ↑$50M cash runway supports trials through BLA submission
- ↑Strong clinical momentum and positive FDA interactions
Bear says
- ↓Phase III non-inferiority to aflibercept raises binary risk
- ↓BLA timeline may slip due to FDA questions or delays
- ↓Long-term safety and efficacy beyond 48 weeks remain unproven
- ↓Cash runway may tighten amid rising R&D and trial costs
- ↓Dominant competitors could undercut pricing and limit share
- ↓Operational execution and resource allocation risks elevated
Earnings Call · Q4 2020 · Mgmt. Guidance
Updated 09-05-2026bullish
Transcript signals
Bull points
- we now have a clear path to targeted BLA submission for ADD-MO22 in wet AMD in 2024.
- We believe that ADD-MO2-2 is uniquely positioned, unlike any other treatments on the market or in development, as an advanced gene therapy product with the potential to be a one-and-done approach for millions of people living with wet AMD globally.
- Focusing on the 2E11 dose, you can see that two-thirds of the patients are injection-free for a follow-up of 68 weeks, and there's an 85% reduction in annualized anti-VEGF frequency.
Bear points
- The sooner we have this treatment for our patients, the sooner we can help patients around the world who are suffering from this chronic disease.
- The sooner we have this treatment for our patients, the sooner we can help patients around the world who are suffering from this chronic disease.
Read full transcript analysis ›